ストックスクリーナーアプリを入手
9.5037
0.21%
-0.0563
前日終値:
$9.56
開ける：
$9.35
24時間の取引高:
495.89K
Relative Volume:
0.16
時価総額：
$1.49B
収益：
$62.04M
当期純損益:
$-533.34M
株価収益率:
-2.4244
EPS:
-3.92
ネットキャッシュフロー:
$-473.07M
1週間 パフォーマンス:
+2.36%
1か月 パフォーマンス:
+37.86%
6か月 パフォーマンス:
+81.02%
1年 パフォーマンス:
+16.06%
1日の値動き範囲:
$9.24
$9.57
1週間の範囲:
$8.75
$10.09
52週間の値動き範囲:
$4.155
$10.94
Vir Biotechnology Inc Stock (VIR) Company Profile
名前
Vir Biotechnology Inc
セクター
電話
415-906-4324
住所
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
9.51 | 1.50B | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.38 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
769.92 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
727.71 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.09 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
294.43 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-03 | 開始されました | Evercore ISI | Outperform |
| 2025-08-27 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-09-08 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-03-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-02-21 | アップグレード | Goldman | Neutral → Buy |
| 2023-01-27 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | 開始されました | SVB Leerink | Outperform |
| 2022-09-09 | 開始されました | Morgan Stanley | Underweight |
| 2022-03-03 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-09-22 | ダウングレード | Goldman | Buy → Neutral |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-01-27 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-05 | 開始されました | BofA Securities | Buy |
| 2020-09-14 | アップグレード | Goldman | Neutral → Buy |
| 2020-09-11 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-08-20 | 開始されました | Needham | Buy |
| 2020-03-19 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-03-13 | ダウングレード | Goldman | Buy → Neutral |
| 2020-02-27 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-11-14 | 開始されました | Robert W. Baird | Neutral |
| 2019-11-05 | 開始されました | Barclays | Overweight |
| 2019-11-05 | 開始されました | Cowen | Outperform |
| 2019-11-05 | 開始されました | Goldman | Buy |
| 2019-11-05 | 開始されました | JP Morgan | Overweight |
すべてを表示
Vir Biotechnology Inc (VIR) 最新ニュース
According to the latest filing disclosed by the U.S. Securities and Exchange Commission (SEC), biotechnology company Vir Biotechnology, Inc. has announced a significant personnel appointment. - Bitget
Vir Biotechnology Appoints Marianne De Backer As President In Addition To CEO On March 4, 2026SEC Filing - TradingView
Vir Biotechnology Names CEO Marianne De Backer as President - TipRanks
Vir Biotechnology appoints Marianne De Backer as president in addition to CEO on March 4, 2026SEC filing - marketscreener.com
Vir Biotechnology (NASDAQ:VIR) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
VIR: HC Wainwright & Co. Raises Price Target to $20, Maintains B - GuruFocus
Assessing Vir Biotechnology (VIR) Valuation After Astellas Alliance And VIR-5500 Phase 1 Update - simplywall.st
Vir Biotechnology, Inc. (VIR) Presents at 2026 ASCO Genitourinary Cancers SymposiumSlideshow - Seeking Alpha
VIR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Insider Sell: Vicki Sato Sells 22,000 Shares of Vir Biotechnology Inc (VIR) - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares - MarketBeat
22,000 Vir Biotechnology (VIR) shares sold under 10b5-1 plan - Stock Titan
VIR (NASDAQ: VIR) files Form 144 for 88,000 pre-IPO shares - Stock Titan
Vir Biotechnology closes $172.5 million public offering of common stock - Investing.com
Vir Biotechnology Raises Capital Through Public Stock Offering - TipRanks
Vir Biotechnology closes $172.5 million public offering of common stock By Investing.com - Investing.com UK
Vir Biotechnology completes $172.5M follow-on offering, issues 20.29M shares - TradingView
[8-K] Vir Biotechnology, Inc. Reports Material Event | VIR SEC FilingForm 8-K - Stock Titan
Vir Biotechnology Astellas Deal Puts VIR-5500 And Valuation In Focus - Yahoo Finance
Vir Biotechnology (NASDAQ:VIR) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Watch Vir Bio CEO on Cancer Treatment Progress, Potential Deals - Bloomberg
Vir Biotechnology, Inc. (VIR) Stock Analysis: An Investor’s Look at a Potential 116.98% Upside - DirectorsTalk Interviews
Insider Selling: Vir Biotechnology (NASDAQ:VIR) CFO Sells 1,634 Shares of Stock - MarketBeat
Brent Sabatini Sells 1,430 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat
Mark Eisner Sells 1,616 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat
Vir Biotechnology (NASDAQ:VIR) EVP Verneuil Vanina De Sells 3,117 Shares - MarketBeat
Vir Biotechnology Announces Significant Common Stock Offering - TipRanks
Vir Biotechnology prices $150M stock offering at $8.50/share By Investing.com - Investing.com Australia
Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 42,377 Shares - MarketBeat
Vir Biotechnology (NASDAQ:VIR) CEO Backer Marianne De Sells 14,762 Shares - MarketBeat
Leerink Maintains Outperform on Vir Biotechnology, Inc. (VIR) Feb 2026 - Meyka
Vir Biotechnology (NASDAQ: VIR) plans $141.1M stock sale - Stock Titan
Vir Biotechnology (VIR) to Sell 17.65M Shares; Astellas Collaboration Disclosed - Stock Titan
Vir Biotechnology (VIR) director Sato exercises options and sells 42,377 shares - Stock Titan
[Form 4] Vir Biotechnology, Inc. Insider Trading Activity - Stock Titan
Vir Biotechnology (VIR) CFO executes automatic 10b5-1 share sale for taxes - Stock Titan
Vir Biotechnology (VIR) CMO reports 3,505-share Rule 10b5-1 stock sale - Stock Titan
Vir Biotechnology (VIR) EVP’s 10b5-1, tax-driven sales total 16,817 shares - Stock Titan
Vir Biotechnology to Participate in Upcoming Investor Conferences - Business Wire
Leerink raises Vir Biotechnology stock price target on partnership - Investing.com
Latham & Watkins Advises on Vir Biotechnology’s US$150 Million Public Offering of Common Stock - Latham & Watkins LLP
Vir Biotechnology (NASDAQ:VIR) Shares Gap DownShould You Sell? - MarketBeat
Vir Biotechnology (VIR) Earnings Call Transcript - AOL.com
Vir Biotechnology Prices $150 Mln Public Offering At $8.50 Per Share, Stock Down - Nasdaq
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? - Stocktwits
Vir Biotechnology stock tumbles on discounted share offering - Investing.com
Vir Biotechnology stock tumbles on discounted share offering By Investing.com - Investing.com India
Vir Biotechnology announces pricing of public offering of common stock at $8.50 per share - marketscreener.com
Vir Biotechnology (VIR) Prices Public Offering at $8.50 Per Shar - GuruFocus
Vir Biotechnology Announces Pricing of Public Offering of Common Stock - PharmiWeb.com
Vir Biotechnology launches $200M public stock offering - MSN
Vir Biotechnology Inc (VIR) 財務データ
収益
当期純利益
現金流量
EPS
0.50%
大文字化:
|
ボリューム (24 時間):